key: cord-0905617-fhxo7lfs
authors: Taeschler, Patrick; Cervia, Carlo; Zurbuchen, Yves; Hasler, Sara; Pou, Christian; Tan, Ziyang; Adamo, Sarah; Raeber, Miro E.; Bächli, Esther; Rudiger, Alain; Stüssi‐Helbling, Melina; Huber, Lars C.; Brodin, Petter; Nilsson, Jakob; Probst‐Müller, Elsbeth; Boyman, Onur
title: Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures
date: 2022-04-08
journal: Allergy
DOI: 10.1111/all.15302
sha: fe671cb1c36a844f808f5fc01ab20bf8ab324d4f
doc_id: 905617
cord_uid: fhxo7lfs

BACKGROUND: Several autoimmune features occur during coronavirus disease 2019 (COVID‐19), with possible implications for disease course, immunity, and autoimmune pathology. In this study, we longitudinally screened for clinically relevant systemic autoantibodies to assess their prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of COVID‐19. METHODS: We performed highly sensitive indirect immunofluorescence assays to detect antinuclear antibodies (ANA) and antineutrophil cytoplasmic antibodies (ANCA), along with serum proteomics and virome‐wide serological profiling in a multicentric cohort of 175 COVID‐19 patients followed up to 1 year after infection, eleven vaccinated individuals, and 41 unexposed controls. RESULTS: Compared with healthy controls, similar prevalence and patterns of ANA were present in patients during acute COVID‐19 and recovery. However, the paired analysis revealed a subgroup of patients with transient presence of certain ANA patterns during acute COVID‐19. Furthermore, patients with severe COVID‐19 exhibited a high prevalence of ANCA during acute disease. These autoantibodies were quantitatively associated with higher SARS‐CoV‐2‐specific antibody titers in COVID‐19 patients and in vaccinated individuals, thus linking autoantibody production to increased antigen‐specific humoral responses. Notably, the qualitative breadth of antibodies cross‐reactive with other coronaviruses was comparable in ANA‐positive and ANA‐negative individuals during acute COVID‐19. In autoantibody‐positive patients, multiparametric characterization demonstrated an inflammatory signature during acute COVID‐19 and alterations of the B‐cell compartment after recovery. CONCLUSION: Highly sensitive indirect immunofluorescence assays revealed transient autoantibody production during acute SARS‐CoV‐2 infection, while the presence of autoantibodies in COVID‐19 patients correlated with increased antiviral humoral immune responses and inflammatory immune signatures.

Acute coronavirus disease 2019 (COVID-19) causes a large clinical spectrum, ranging from a mild condition in the majority of cases to fatal disease in 1-2% of subjects. [1] [2] [3] Several features of acute COVID-19 resemble clinical manifestations of systemic inflammatory and autoimmune diseases, such as fatigue, myalgia, hyperinflammation, thrombosis, and skin rashes. 3, 4 Furthermore, COVID-19 may trigger the onset of autoimmune pathology, as reported for Guillain-Barré syndrome, antiphospholipid syndrome, vasculitis, and multisystem inflammatory syndrome in children. [5] [6] [7] [8] [9] Vice versa, autoimmune phenomena have been connected to the pathogenesis of severe COVID-19. Pre-existing autoantibodies targeting the type I interferon pathway have been found in about 10% of COVID-19 cases with critical disease. [10] [11] [12] Other acute or chronic viral infections have been associated with autoimmune responses, which have been proposed to arise by molecular mimicry, epitope spreading, or bystander activation. 13 Various autoantibodies have been described in association with COVID-19, including antinuclear antibodies (ANA), [14] [15] [16] [17] [18] [19] [20] antineutrophil cytoplasmic antibodies (ANCA), 15, 16, 21 antiphospholipid antibodies, 5, 8, 14, 17, 19, 22 and antibodies targeting different extracellular antigens. 11, 16 While the presence of different autoantibodies has been associated with severe COVID-19 and worse outcome, 11, 15, [17] [18] [19] it remains unclear to what extent autoantibodies are triggered by acute infection, even though transient autoreactivity and new development of autoantibodies have been suggested in a subgroup of COVID-19 patients. 16, 20 Furthermore, several aspects of autoantibodies in COVID-19, including their interplay with virus-specific humoral responses and their durability after acute infection, need further elucidation. In this study, we comprehensively characterized autoantibodies by using highly sensitive indirect immunofluorescence (IIF) assays in a multicentric prospective cohort of 227 individuals.

We performed a comprehensive immunological characterization of 175 individuals with confirmed COVID-19 up to 1 year after infection ( Figure 1A and Table 1, Table S1 ), including autoantibody screening by IIF, serum proteomics, and serological profiling. 41 individuals with autoantibodies in COVID-19 patients correlated with increased antiviral humoral immune responses and inflammatory immune signatures.

antinuclear antibodies, autoantibodies, COVID-19, SARS-CoV-2, VirScan

In a multicentric cohort of 175 COVID-19 patients, 11 vaccinated individuals, and 41 unexposed controls, we measured ANA and ANCA, along with serum proteomics and virome-wide serological profiling. Paired analysis revealed the transient presence of ANA patterns and ANCA during acute COVID- 19 . The presence of autoantibodies correlated with increased virus-specific humoral immune responses and a proinflammatory immune signature.

negative history and serology for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were included as controls ( Figure 1A and Table 1 ). Furthermore, eleven unexposed individuals were sampled before and after vaccination with BNT162b2 (Table S2) .

Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41 (41.4%) healthy individuals ( Figure 1B) , which followed an insignificant trend toward higher ANA prevalence in older participants ( Figure S1A ). The prevalence of ANA Figure 1F ,G), which returned to ranges seen in healthy individuals after 6 months (5.1%, p = .61) and 1 year (14.3%, p = .15) ( Figure 1H ,I).

In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently, particularly during acute COVID-19

( Figure 1J -M). Moreover, ANCA showed a tendency to be more frequent in ANA-positive (14.3%) compared with ANA-negative (5.5%) individuals during acute COVID-19 (p = .06) ( Figure 1K ).

To gain a qualitative appreciation, we classified ANA patterns ac- Antineutrophil cytoplasmic antibodies patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic ( Figure 2H ). Severe COVID-19

patient newly exhibited positive ANCA at follow-up ( Figure 3E ,F).

Collectively, we found that a subgroup of individuals shows ANA and atypical ANCA production during the acute phase of COVID-19, which usually subsides during follow-up.

To elucidate the influence of autoantibody production during acute infection, we investigated the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2. We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA)

and IgG titers and found that the presence of ANA was associated with higher concentrations of S1-specific antibodies in COVID-19

patients during acute disease, which extended to 6 months after recovery ( Figure 4A ). Conversely, 1 year after recovery, we did not observe any differences ( Figure S3 ). The presence of ANA correlated significantly with S1-specific IgG levels even after accounting for age, disease severity, and sampling time point in a multiple linear regression model, which was not the case of S1-specific IgA ( Figure 4B , Table S3 ). Similarly, we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested positive for ANCA during acute disease ( Figure 4C ).

To elucidate whether autoantibodies were associated with an increased humoral immune response only after natural SARS-CoV-2 infection or also after other antigen-specific immune responses, we measured ANA and S1-specific antibodies in 11 individuals before and after COVID-19 vaccination with BNT162b2 ( Figure 4D -F, Table   S2 ). Although a tendency of an increased ANA prevalence following the first vaccine shot was apparent, no significant difference was observed between sampling timepoints ( Figure 4D ). We observed higher S1-specific IgA in ANA-positive individuals when combining data from 2 and 4 weeks after the first vaccine shot, whereas no difference was observed for IgG ( Figure 4E ,F). In summary, these findings suggest the presence of autoantibodies is associated with increased S1-specific humoral responses following acute COVID-19 up to 6 months after recovery and following SARS-CoV-2 vaccination.

Next, we sought to investigate qualitative aspects of antibody responses during acute COVID-19 with respect to previous antiviral humoral responses in ANA-positive and ANA-negative individuals.

Based on the phage immunoprecipitation sequencing (PhIP-seq) technology (VirScan), 26 we performed human virome-wide serological profiling in 97 acute COVID-19 patients and 18 healthy controls.

We assessed the results of antibodies directed to 112 different viruses (Table S4) To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological profiles on a singular epitope level. We found a significantly higher (p < .05) proportion of COVID-19 patients tested positive for a total of 18 CoV epitopes compared with healthy controls, of which 16 were in the spike and two in the nucleoprotein ( Figure 5D , Figure S4A ). Since healthy individuals tested negative for these but positive for only one epitope ( Figure 5D ,E), we with severe COVID-19 tested positive for significantly more crossreactive antibodies than mild disease patients ( Figure 5E ). However, no significant difference was observed in ANA-positive compared with ANA-negative patients ( Figure 5F ), although the proportion of ANA-positive patients that tested positive was slightly higher for most cross-reactive epitopes ( Figure 5G ).

To explore potential correlations of ANA with humoral responses against other viruses, we compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes were detected more frequently (p < .005) in ANA-positive, but not in ANA-negative, individuals ( Figure 5H) . Three of the identified peptides were located on Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope hits, independent of age ( Figure S4B ). When combining data of all available epitopes, we found significantly more hits in ANA-positive compared with ANA-negative participants, which was most pronounced at a younger age ( Figure 5I) . Thus, human Table 2) , and none of the study participants developed a symptomatic autoimmune disease following SARS-CoV-2 infection. We found a higher prevalence of comorbidities in autoantibody-positive patients, including hypertension and heart disease, but no significant sex difference ( Table 2) .

A multivariate analysis with 130 variables, including demographic parameters, routine diagnostic measurements, and inflammation markers obtained by proteomics (Table S5) Table   S6 ). Interestingly, we also observed differences in Ig subclasses, with significantly higher IgG1 and significantly lower IgM in ANA-positive individuals ( Figure 6H) . Furthermore, marked changes in B-cell subsets were apparent, with higher frequencies of IgD + CD27naïve B cells and lower frequencies of IgD + CD27 + nonswitched and IgD -CD27 + switched memory B cells in ANA-positive individuals ( Figure 6I ).

Altogether, in autoantibody-positive COVID-19 patients, we found an inflammatory signature during acute disease resembling alterations found in severe disease and changes in inflammation markers, Ig subclasses, and B cells 6 months after recovery.

Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following viral infections have been well described, 28, 29 their significance has remained ill-defined. In this study, we used highly sensitive assays to detect ANA and ANCA, representing sys- Thirdly, we observed higher S1-specific antibody titers in autoantibody-positive COVID-19 patients, indicating a more robust, functional humoral immune response, since S1-specific antibodies have been associated with virus-neutralizing capacity. [46] [47] [48] Similar to our results, recent reports found increased antiviral humoral responses in autoantibody-positive individuals during acute COVID-19, although the interrelation remained unclear. 16, 19, 22 Interestingly 

Following written informed consent, adult individuals were recruited for medical history and blood sampling between April 2020

and May 2021. The study was approved by the Cantonal Ethics

Committee of Zurich (BASEC #2016-01440). The cohort comprised mild and severe COVID-19 patients, healthy controls, and vaccinated individuals. (Table 1, Table S1) (Table S4) . Colors indicate participant groups with higher mean epitope hits per species. Viral species with significant difference (p < .005) between COVID-19 patients and healthy controls are shown as large colored dots. Black crosses indicate insignificant differences of coronaviruses (p > .005). ( (Table S5) including data of healthy controls (n = 28) and acute COVID-19 patients (n = 146). Participants with missing values were excluded from this analysis. 95% confidence ellipses (t-distributed) are shown for healthy controls and severe COVID-19 patients. (B) Loadings (variable coordinates) of the PCA depicted in (A), with each parameter shown as an individual dot. Colors indicate the group of COVID-19 patients with higher mean for each parameter, and parameters with significant differences (p < .05) are represented as large dots, and selected parameters are annotated (Table S5) 

Immunoassays for Ig subsets, anti-SARS-CoV-2 spike S1-specific IgA and IgG, interleukin (IL)-1β, IL-2, IL-5, IL-6, IL-10, IL-12, interferonγ (IFNγ), sIL-2Rα, and tumor necrosis factor α (TNFα),

were performed in accredited laboratories at University Hospital Zurich. Serum Ig subsets were quantified on an Optilite ® turbidimeter (The Binding Site Group). S1-specific IgA and IgG were measured by enzyme-linked immunosorbent assays (ELISA) (Euroimmun), as established. 46 IL-1β, IL-2, IL-6, IFNγ, and sIL-2Rα

were determined by ELISA (R&D Systems) on Opsys Reader™ (Dynex). IL-5, IL-10, and IL-12 were measured by cytometric bead assays (BD Biosciences) on a Navios cytometer (Beckman Coulter).

TNFα was determined with a kit (R&D Systems) using MagPix ® (ThermoFisher Scientific).

As established, 55 blood samples were processed and analyzed in accredited laboratories at University Hospital Zurich. Blood samples were lysed with VersaLyse, fixed with IOTest3 solution, and stained with antibodies (Beckman Coulter; Table S7 ). Absolute cell counts were determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter).

Serum samples were analyzed by a proximity extension assaybased technology 92-plex inflammation panel (Olink ® ), as established. 33, 55, 56 Six parameters were excluded because less than 50% of samples showed results above the detection limit.

As established, 7,57 serum samples were inactivated, normalized for total IgG concentration, and incubated as duplicates with a bacteriophage library displaying linear, 56-amino acid long viral epitopes.

IgG-phage complexes were captured with magnetic beads, lysed, and quantified by next-generation sequencing. Blank beads samples were used as negative controls. Reads were mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools. A previously described binning strategy was used to identify positivity for epitopes, 58 with a minimum z-score of 3.5 for both sample replicates compared with negative controls. Results for a total of 112 different human viruses were included in the further analysis (Table S4) , whereas eukaryotes, prokaryotes, non-human viruses, and human viruses with no variance or a maximal summed epitope hit count below three were excluded.

Statistical analyses were performed using R (version 4.1.0). Unless otherwise specified, the between-group comparison was performed using two-tailed, nonparametric, unpaired testing (Mann-Whitney 

Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB), and an Innovation Grant of University Hospital Zurich (to OB)

Bachmann for their support, and the members of the Boyman Laboratory for helpful discussions. The study overview graphic was generated with BioRender.com. Open access funding provided by Universitat Zurich

contributed to patient recruitment and data collection, analysis, and interpretation. C.C. contributed to patient recruitment, data collection, and data interpretation

Ziyang Tan

Petter Brodin

Clinical characteristics of coronavirus disease 2019 in China

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

COVID-19 and autoimmune diseases

Coagulopathy and antiphospholipid antibodies in patients with covid-19

Guillain-Barré syndrome associated with SARS-CoV-2

The immunology of multisystem inflammatory syndrome in children with COVID-19

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Incident systemic rheumatic disease following COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Diverse functional autoantibodies in patients with COVID-19

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease

Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19

SARS-CoV-2 infection as a trigger of autoimmune response

New-onset IgG autoantibodies in hospitalized patients with COVID-19

COVID-19 and immunological dysregulation: can autoantibodies be useful?

Autoantibodies in moderate and critical cases of COVID-19

Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19)

Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19. medRxiv

Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak

Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins

Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns

Anti-neutrophil cytoplasmic antibodies and their clinical significance

Neutrophil extracellular traps in tissue pathology

Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Autoantibodies and common viral illnesses

Endogenous polyclonal anti-IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation

Predicted B cell epitopes highlight the potential for COVID-19 to drive self-reactive immunity

Molecular mimicry may explain multi-organ damage in COVID-19

Cytokine storm

A distinct innate immune signature marks progression from mild to severe COVID-19

Neutrophil extracellular traps in COVID-19

Neutrophils in COVID-19

Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome

The regulatory effects of interleukin-4 receptor signaling on neutrophils in type 2 immune responses

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination

Increasing prevalence of antinuclear antibodies in the United States

The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease

Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients

Autoantibodypositive healthy individuals display unique immune profiles that may regulate autoimmunity

Serum IgG subclasses in autoimmune diseases

Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals

Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses

Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19

Signature of long-lived memory CD8 + T cells in acute SARS-CoV-2 infection

COVID-19 Clinical management: living guidance. World Health Organization

Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19

Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood

The repertoire of maternal anti-viral antibodies in human newborns

Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens

Additional supporting information may be found in the online version of the article at the publisher's website.